Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital

Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity BARCELONA, Spain, DÜSSELDORF, Germany

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Japan ,Castellbisbal ,Germany ,Paris ,France General ,France ,Turkey ,China ,Japanese ,Laboratorios Lesvi ,Miquel Bachs ,Thomas Dierks ,Alvarez Marsal ,Paul Hastings ,Prnewswire Neuraxpharm Group ,Neuraxpharm Group ,Rothschild Co ,Equity Exchange ,Bain Company ,Clifford Chance ,European Growth Private Equity Fund ,Keensight Capital ,European Growth Buyout ,General Manager ,Gold Award ,Private Equity Exchange ,Best European Growth Private Equity ,Neuraxpharm ,Degrees ,Divestment ,Inhalation ,Specialist ,Nke ,Eensight ,Capital ,